ストックスクリーナーアプリを入手
7.57
0.93%
0.07
プレマーケット:
7.70
0.13
+1.72%
前日終値:
$7.50
開ける：
$7.55
24時間の取引高:
224.54K
Relative Volume:
0.76
時価総額：
$427.21M
収益：
-
当期純損益:
$-72.89M
株価収益率:
-3.1281
EPS:
-2.42
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
+2.71%
1か月 パフォーマンス:
-20.82%
6か月 パフォーマンス:
-32.41%
1年 パフォーマンス:
-2.07%
1日の値動き範囲:
$7.485
$7.74
1週間の範囲:
$7.29
$7.954
52週間の値動き範囲:
$7.16
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
ATXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
7.57 | 427.21M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-29 | 開始されました | TD Cowen | Buy |
| 2023-03-28 | 開始されました | Evercore ISI | Outperform |
Astria Therapeutics Inc (ATXS) 最新ニュース
Where are the Opportunities in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus Price Target from Brokerages - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Barclays PLC Has $1.02 Million Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics plans phase 3 trial for HAE drug - Investing.com
Astria Therapeutics Unveils Phase 3 ALPHA-ORBIT Trial Design for HAE Treatment Navenibart - StockTitan
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Jane Street Group LLC Has $404,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Jane Street Group LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Astria Therapeutics Awards Stock Options to New Employees Under Inducement Plan - StockTitan
Geode Capital Management LLC Trims Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Geode Capital Management LLC Has $10.50 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Barclays PLC Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decrease in Short Interest - MarketBeat
(ATXS) Investment Analysis - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 3.4%Here's What Happened - MarketBeat
State Street Corp Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
State Street Corp Sells 495,436 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.60 - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $613,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics expands stock incentive plan - Investing.com
Astria Therapeutics Expands Stock Incentive Plan - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages - MarketBeat
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis - BioWorld Online
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
FDA clears Astria Therapeutics' new AD drug for trial By Investing.com - Investing.com Canada
Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results - StockTitan
Astria Therapeutics, Inc. Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Marketscreener.com
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
(ATXS) Long Term Investment Analysis - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLC - Defense World
Fmr LLC Buys 1,767,714 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Intech Investment Management LLC Makes New $228,000 Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Redmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
RA Capital Management L.P. Has $56.21 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Walleye Capital LLC Has $1.92 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Awards Key Inducement Stock Options to Strengthen Leadership Team - StockTitan
Vestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Trend Tracker for (ATXS) - Stock Traders Daily
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema - Seeking Alpha
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60 - MarketBeat
Astria Therapeutics Reports Q3 2024 Financial Results - MSN
Astria Therapeutics Inc (ATXS) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):